SynthesisJournal of neurology2012
Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value.
Synthesis in Journal of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 7 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Botulinum toxin type A versus anticholinergics for cervical dystonia.The Cochrane database of systematic reviews · 2021Pooled it
- Botulinum toxin type A therapy for blepharospasm.The Cochrane database of systematic reviews · 2020Pooled it
- Botulinum toxin type A therapy for cervical dystonia.The Cochrane database of systematic reviews · 2020Pooled it
- Botulinum toxin type A therapy for cervical dystonia.The Cochrane database of systematic reviews · 2017Pooled it
- Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.The Cochrane database of systematic reviews · 2016Pooled it
- Botulinum toxin type B for cervical dystonia.The Cochrane database of systematic reviews · 2016Pooled it
- Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia.BMC neurology · 2014Pooled it
- Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy.Toxins · 2018Trial
- Clinical and Genetic Spectrum of ANO3-Related Dystonia with Treatment Responses in a Chinese Cohort.Genes · 2026Article
- Article
- Prism and Maddox rod test as a reliable tool for surgical targeting in small-angle AACE.Scientific reports · 2025Article
- Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity.Toxins · 2025Article
- Neurosurgical and pharmacological management of dystonia.World journal of psychiatry · 2024Review
- Fundamental Concepts of Bipolar and High-Density Surface EMG Understanding and Teaching for Clinical, Occupational, and Sport Applications: Origin, Detection, and Main Errors.Sensors (Basel, Switzerland) · 2022Review
- A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.Journal of rehabilitation medicine · 2021Article
- The role of pallidum in the neural integrator model of cervical dystonia.Neurobiology of disease · 2019Article
- Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment.Clinical drug investigation · 2018Review
- The effect of a single botulinum toxin treatment on somatosensory processing in idiopathic isolated cervical dystonia: an observational study.Journal of neurology · 2018Observational
- Treatment of focal dystonia involving multiple muscles with a single injection of botulinum toxin A to 1 muscle: A case report.Medicine · 2018Article
- Stroke-induced resolution of primary blepharospasm: evidence for the lenticular nucleus as a control candidate.BMJ case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal dystonia is a common, invalidating neurologic condition characterized by involuntary, sustained muscle contractions causing twisting movements and abnormal postures in one body part. Currently, botulinum toxin is the treatment of first choice. We performed a systematic review towards the pharmaco-therapeutic and pharmaco-economic value of botulinum toxin as treatment for focal dystonia, which yielded the following results. Botulinum toxin is the most effective treatment for reducing dystonic symptoms measured with dystonia-specific and general questionnaires, and pain in patients with focal dystonia. Seventy-one percent of patients with cervical dystonia had a reduction in neck pain compared to 12 % in placebo groups. Adverse events occur in 58 % of patients during treatment with botulinum toxin compared to 46 % treated with placebo. Especially dry mouth, neck weakness, dysphagia, and voice changes are common. Adverse events are usually mild and self-limiting. Health-related quality of life, measured with the SF-36 is 20-50 points lower in patients with focal dystonia compared to controls and the effect of botulinum toxin on health-related quality of life is unclear. Botulinum toxin treatment is expensive because the drug itself is expensive. Yearly costs for treating a patient with focal dystonia with botulinum toxin range from EUR 347 to EUR 3,633 and the gain in QALYs with BTX treatment is small. Focal dystonia impairs the productivity and the ability to work. At start of botulinum toxin treatment only 47-50 % was working. Botulinum toxin partly improves this. Overall, we conclude that botulinum toxin is an expensive drug with good effects. From a societal perspective, the costs may well weigh up to the regained quality of life. However, the available literature concerning costs, health-related quality of life and labor participation is very limited. An extensive cost-effectiveness study should be performed incorporating all these aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.